CuraTeQ Biologics achieves milestone in Omalizumab biosimilar development

By on    Pharma Industry News  

CuraTeQ Biologics achieves milestone in Omalizumab biosimilar development

CuraTeQ Biologics Private Limited, a fully integrated arm of Aurobindo Pharma Ltd, has announced significant progress in its biosimilar program, revealing that its Omalizumab biosimilar candidate, BP11, has successfully met the primary endpoints in a Phase 1 trial. The study, engaging 165 healthy volunteers across Australia and New Zealand, was designed to compare BP11 with […]

FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment

By on    Pharma Industry News  

FDA approves Genentech’s Xolair for food allergies: A new horizon in allergy treatment

The U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) for reducing allergic reactions, including anaphylaxis, that may occur with accidental exposure to foods in individuals aged 1 year and older with IgE-mediated food allergy. This marks a significant milestone as Xolair, produced by Genentech, a member of the Roche Group, becomes the first […]